KURA Kura Oncology Inc

$KURA JP Morgan analyst Priyanka Grover initiated coverage on Kura Oncology, Inc. (NASDAQ:KURA) with an Overweight rating and announced a price target of $30

$KURA - I think accumulation will start in KURA over next few weeks. It is one of the least risk stock with huge potential, good management team (With CEO Troy buying 200k shares at around $ 12 in last 2 months). But this is for longer term hold. Very

$KURA analyst target $30 yet $BMEA at at $1:30. Something not not sit right at all here, so I am very bullish on BMEA

$KURA do they know what I know? • H.C. Wainwright — $40 (Buy) • Wedbush — $38 (Outperform; raised from $36 in mid-Aug) • BofA — ~$30–$31 (Buy) • Barclays — $28 (Buy) • Mizuho — $25 (Buy) • Citizens / JMP, Raymond James, others — $24 • Lake Street — $23 (Buy)

UBS reiterated $KURA Buy-$15 and said -- KURA's 2Q26 metrics reinforced strong early Komzifti launch execution, with accelerating new patient starts, growing repeat prescribing, and favorable access dynamics supporting continued uptake. $SNDX $BMY AMGN ABBV - RHHBY UBS added — Management increasingly emphasized Komzifti's potential as a frontline AML backbone therapy, citing high current combination use (~40%), upcoming FLT3 combination data, encouraging frontline efficacy, and the prospect for multi-year treatment duration. Despite growing competition, mgmt remains confident that Komzifti's tolerability, combination flexibility, and clean long-term safety profile will become increasingly important differentiators as menin inhibitors move earlier in treatment. Separately, darlifarnib continues to emerge as a promising combination platform across targeted therapies, with additional data expected in 2027 helping further validate the strategy.

$KURA - looks like below CNBC Pro article (just posted < 1 hour ago) is about KURA based on JPM initiation with $30 PT. And that is why SP started flying quickly. https://www.cnbc.com/2026/10/01/this-biotech-making-precision-medicines-for-cancer-could-nearly-triple-says-jpmorgan.html Very Very

$KURA KURA, today announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for diabetes. KO-7246 regenerated functional β-cell mass, demonstrated durable glycemic control, and increased endogenous insulin production in preclinical models of Type 1 and Type 2 diabetes. In human islets, KO-7246 selectively increased β-cell proliferation and improved glucose-responsive insulin secretion. Together, the findings establish a differentiated preclinical profile including validated activity as a menin inhibitor, durable disease-relevant activity, and confirmed translation to a human-islet setting.

Citizens reit'd $KURA Mkt OP-$24 & said -- Yesterday, Kura and Caspian Therapeutics presented preclinical data for KO-7246, highlighting potential best-in-class menin inhibitor results for the treatment of diabetes. $LLY $NVO VKTX VRTX KYKOF SNDX BMY ABBV RHHBY PFE Citizens added — With the Ziftomenib launch and multiple registrational studies underway, updated ziftomenib combo data expected at ASH, the FTI platform to enter registrational studies in 2028, and a cash position of $519MM, we believe Kura shares represent an attractive investment opportunity given the recent weakness.

$KURA Preclinical data for Kura Oncology's new menin inhibitor, KO-7246, will be presented at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting on September 29, 2026. Presentation Details Title: Next-generation menin inhibitor KO-7246 regenerates beta cell mass in diabetic rodent and human islet models Presenter: Francis Burrows, Ph.D., Chief Scientific Officer Session: OP 05 From Islet Failure to Regeneration: New Strategies in Type 2 Diabetes Date and Time: September 29, 2026, 11:15–11:30 a.m. CEST

$KURA 14.82 million shares sold short. 18% of float 9 days to cover. Kura reps have been visiting hematologists the rise of komzifti is upon us.

$KURA wilson’s Insider buy hasnt aged well. But all of biotech is getting hammered. I bought at 12 and 10. Gonna hold, but yeah, this is classic biotech investing at its finest. Gl to all.

$KURA Kura Oncology initiated with an Overweight at JPMorgan JPMorgan initiated coverage of Kura Oncology with an Overweight rating and $30 price target. The firm believes Komzifti provides a "floor" for the shares with potential upside from darlifarnib. JPMorgan is positive on Kura's transition into a commercial-stage oncology company with Komzifti in relapsed/refractory NPM1-mutant acute myeloid leukemia. A clean label with no ziftomenib-related Qblack-box warning "is a clear differentiator among the menin class," the analyst tells investors in a research note. The firm sees total sales of $1.5B and says darlifarnib, a next-generation farnesyl transferase inhibitor, broadens Kura beyond a single menin inhibitor launch by potentially expanding into solid-tumor combinations.

$KURA under 8 buhaaaaa Maybe Wilson has another preeeeeeeeeeeeeeeeeee preeeeeeeeeeeeee drug and another spinoff press release and webcast first in class bull shit company name press hype raise money inc. rofl

$KURA another webcast coming on an early per-trial drug without even knowing it has any chance of working lol Wilson just spams any news he can. no money for trials and have to fit the bill until 2029 for zip in the usa. He is making reference of caprian as a totally different company that is partnering with them as it was a shell within Kura for years. fake news to pump the share price as he is looking for issuing stock to raise much needing cash. After 8 months on the market for zipo only 9.1 million the quarter and it would have to be split 50/50 that leaves 4.5 million and Kura fits all the r&d expenses LOL

$KURA dipped under 11. Fair play. Might as well give us some shares under 10 before the rebound.

$KURA New spinoff company wilson bio. They have a new menin drug that could stop stupid people from falling for his bull shit. Webcast in two weeks to discuss the new best in class drug . only stupid people who believe the hype listen in. The raise of money of 25 cents will fund this pre pre pre trial in the year 2145.

$KURA Maybe its time for Kura to put out another bullshit report like Menin inhibitors Kura it could work pre pre pre clinical in Obesity. First in Class!!!! Maybe a spinoff of Kura instead this time Obeskura!

$KURA ok. Found it. Down 20% since insider open market BIG BOY buy. Hmmmmm. Going to start a position, average in until solid reversal.

$KURA Management to host webcast and conference call on October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

$KURA I thought conference call would be today. Why hold conference call 2 weeks after PR? Management to host webcast and conference call on October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –